Chewy reported a 7.7% revenue increase to $3.36 billion in Q1, matching EPS estimates at 43 cents. The customer base grew 3.6% to 21.5 million, with average revenue per user rising 2.4%. However, the company lowered its full-year revenue forecast to $13.4B–$13.55B from $13.6B–$13.75B and projected Q2 EPS of about 36 cents, below Wall Street's 40-cent estimate. CEO Sumit Singh highlighted ongoing market share gains amid a tougher economic environment but signaled cautious outlook due to consumer financial pressures affecting the broader pet industry.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
VINCI has initiated a share buyback program by signing an agreement with an investment services provider to repurchase its shares up to a limit of €200 million. The program runs from June 11 to July 31, 2026, with the purchase price capped by shareho...
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...
VINCI has initiated a share buyback program by signing an agreement with an investment service provider to repurchase its shares up to a value of €200 million. This program runs from June 11 to July 31, 2026, with purchase prices capped by the genera...
Bloom Energy Corp. provides solid oxide fuel cells that deliver clean, reliable electricity, crucial for the growing AI data center industry. RBC Capital set a price target of $335, implying a 40.9% upside from the current $237.77 stock price, driven...
